---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Special populations"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Special populations. Topics: Age: adult participants in the phase 3 trial; Age: eligibility from 18 to 75 years; Pregnancy, nursing, and contraception for 150 days after treatment; Male fertility: spermatogenesis in the six-month non-human primate toxicology study; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/special-populations"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age: adult participants in the phase 3 trial

> “This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-2"></a>

### Age: eligibility from 18 to 75 years

> “Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).”

Source: [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)

<a id="topic-2.1.2.8-3"></a>

### Pediatric participants

No evidence found.

<a id="topic-2.1.2.8-4"></a>

### Pregnancy, nursing, and contraception for 150 days after treatment

> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”
> “Women who are pregnant or nursing.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-5"></a>

### Male fertility: spermatogenesis in the six-month non-human primate toxicology study

> “In February 2022, we reported interim data after completing the in-life dosing portion of our six-month chronic toxicology study in non-human primates.”
> “The only clinically adverse finding at the completion of dosing was a profound impact on spermatogenesis, an expected and well understood effect of KIT inhibition.”
> “Due to the very high concentrations of barzolvolimab at the end of dosing, the recovery period was approximately one year.”
> “As we expected, and consistent with previous findings with KIT blocking antibodies, we were pleased to report in December 2022, that during this recovery period spermatogenesis fully recovered in all male animals as measured by both sperm count and motility.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “In addition to its role in hematopoiesis, KIT signaling is important in other processes and has been described to have a role in hair pigmentation and spermatogenesis.”
> “The effect of CDX‐0159 on fertility parameters will be studied in relevant preclinical models.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

<a id="topic-2.1.2.8-6"></a>

### Sex and body weight: effect on exposure in prurigo nodularis

> “We report the effect of a single dose of barzolvolimab, on safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity, in patients with PN.”
> “Exposure was not influenced by intrinsic and extrinsic participant-specific parameters, including sex, weight, or treatment-emergent antidrug antibody status”

Source: [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)

<a id="topic-2.1.2.8-7"></a>

### Hepatic impairment: normal liver function tests required for enrollment

> “Normal blood counts and liver function tests.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.8-8"></a>

### Renal impairment

No evidence found.

<a id="topic-2.1.2.8-9"></a>

### History of anaphylaxis and HIV, hepatitis B, or hepatitis C infection: exclusion criteria

> “History of anaphylaxis.”
> “Known HIV, hepatitis B or hepatitis C infection.”

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
